ICG plc purchased 311,844 of its own ordinary shares between April 1-2, 2026, as part of a share buyback program announced in February 2026. This buyback supports the issuance of Non-Voting Shares to Amundi, aligning with a strategic partnership announced in November 2025. The repurchased shares will be held in treasury and eventually cancelled in batches, ensuring no dilution for existing shareholders. After the buyback, ICG plc has 287.5 million ordinary shares outstanding, with 6.8 million held in treasury and 1.68 million Non-Voting shares issued.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
